Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. : An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON). - HUDSON

Medienart:

Klinische Studie

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

WHO International Clinical Trials Registry Platform - (2022) vom: 30. Mai Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Patients with non-small cell lung cancer (NSCLC) MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Phase: Phase 2
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-11-2017, Last updated: 2022-11-24

ICTRP ID:

EUCTR2017-002208-28-DE
D6185C00001

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO00438038X